阿戈美拉汀与帕罗西丁对抑郁症的远期疗效及综合生活质量的比较研究  

Comparative study of long-term efficacy and comprehensive quality of life between Agomelatine and Paroxetine in the patients with depression

作　　者：申连城 李遵清 李龙飞 李明真 韩鹏 SHEN Liancheng;LI Zunqing;LI Longfei;LI Mingzhen;HAN Peng(Department of Psychiatry,Shandong Daizhuang Hospital,Shandong Province,Jining272051,China;Department of Imaging,Shandong Daizhuang Hospital,Shandong Province,Jining272051,China)

机构地区：[1]山东省戴庄医院精神科,山东济宁272051 [2]山东省戴庄医院影像科,山东济宁272051

出　　处：《中国当代医药》2022年第22期70-73,共4页China Modern Medicine

基　　金：山东省医药卫生科技发展计划项目(2017WS036)。

摘　　要：目的比较阿戈美拉汀与帕罗西汀对抑郁症的远期疗效及对综合生活质量的影响。方法选取2018年3月至2020年3月在山东省戴庄医院精神科住院治疗的64例抑郁症患者作为研究对象,采用抛硬币分组法将其分为研究组(33例)与对照组(31例)。研究组患者给予阿戈美拉汀抗抑郁剂治疗,对照组患者给予帕罗西汀抗抑郁剂治疗。分别于入院时、出院时及出院1年后,采用汉密顿抑郁量表(HAMD)、健康调查简表(SF-36)比较两组的临床康复效果。结果入院时和出院时,两组患者的HAMD、SF-36总分比较,差异无统计学意义(P>0.05)。出院1年后,研究组患者的HAMD总分低于对照组,差异有统计学意义(P<0.05);出院1年后,研究组患者的SF-36总分高于对照组,差异有统计学意义(P<0.05)。结论阿戈美拉汀治疗抑郁症较帕罗西汀具有良好的远期效果,不仅能有效改善患者的临床症状,稳定病情,而且在提高生活质量方面具有优势。Objective To compare the long-term efficacy and comprehensive quality of life between Agomelatine and Paroxetine in the patients with depression.Methods A total of 64 patients with depression who were hospitalized in the Department of Psychiatry,Shandong Daizhuang Hospital from March 2018 to March 2020 were selected as the research subjects,and they were divided into study group(33 cases)and control group(31 cases)by coin toss method.Patients in the study group were treated with agomelatine Antidepressant,and patients in the control group were treated with Paroxetine antidepressant.The clinical rehabilitation effects of the two groups were compared by Hamilton depression scale(HAMD)and medical outcomes study short-form 36(SF-36)at admission,discharge and 1 year after discharge,respectively.Results At admission and discharge,there were no statistically significant differences in HAMD and SF-36 scores between the two groups(P>0.05).One year after discharge,the total HAMD score in the study group was lower than that in the control group,the difference was statistically significant(P<0.05).One year after discharge,the total score of SF-36 in the study group was higher than that in the control group,the difference was statistically significant(P<0.05).Conclusion Agomelatine has better long-term efficacy than Paroxetine in the treatment of depression,it can not only improve the clinical symptoms effectively and stabilize the condition,but also has advantages in improving the quality of life.

关 键 词：抑郁症 阿戈美拉汀 帕罗西汀 远期疗效 生活质量 

分 类 号：R749.4[医药卫生—神经病学与精神病学]